Proposed legislation could deter Chinese biotechs from listing in U.S.
U.S. bill seeking to tighten auditing rules for foreign companies could be win for HKSE
A Senate bill seeking to tighten auditing rules for U.S.-listed foreign companies could end up pushing more Chinese biotechs to go public in Hong Kong. But months of protests and a proposed new national security law under consideration by Beijing could scuttle the opportunity.
The Holding Foreign Companies Accountable Act, which the U.S. Senate passed with unanimous consent Wednesday, would prohibit securities of a